Systemic Lupus Erythematosus Pipeline Review, H1 2018 - Therapeutic Development & Assessment Analysis with Key Players Involved - ResearchAndMarkets.com
Jun. 12, 2018
DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "Systemic Lupus Erythematosus - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 30, 25, 41, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 8 and 1 molecules, respectively.
Companies MentionedAbbVie Inc AiCuris GmbH & Co KG Amgen Inc Apellis Pharmaceuticals Inc Araim Pharmaceuticals Inc Asahi Kasei Pharma Corp Atlantic Bio Sci LLC Aurinia Pharmaceuticals Inc Bio-Path Holdings Inc Biogen Inc Biotest AG Boehringer Ingelheim GmbH Boston Pharmaceuticals Inc Bristol-Myers Squibb Co Carna Biosciences Inc Celgene Corp Cells for Cells SA CuraVac Inc Domainex Ltd Eisai Co Ltd Eli Lilly and Co Epsilon-3 Bio Ltd F. Hoffmann-La Roche Ltd Gilead Sciences Inc GlaxoSmithKline Plc Immungenetics AG Janus Biotherapeutics Inc Johnson & Johnson Merck & Co Inc Merck KGaA Nippon Chemiphar Co Ltd Novartis AG Pfizer Inc Takeda Pharmaceutical Co Ltd Xencor Inc
Key Topics CoveredIntroduction Systemic Lupus Erythematosus - Overview Systemic Lupus Erythematosus - Therapeutics Development Systemic Lupus Erythematosus - Therapeutics Assessment Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development Systemic Lupus Erythematosus - Drug Profiles Systemic Lupus Erythematosus - Dormant Projects Systemic Lupus Erythematosus - Discontinued Products Systemic Lupus Erythematosus - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/xbc8ff/systemic_lupus?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005744/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/12/2018 06:53 AM/DISC: 06/12/2018 06:53 AM